Maarten Boers1,2, Dorcas E Beaton1,2, Beverley J Shea1,2, Lara J Maxwell1,2, Susan J Bartlett1,2, Clifton O Bingham1,2, Philip G Conaghan1,2, Maria Antonietta D'Agostino1,2, Maarten P de Wit1,2, Laure Gossec1,2, Lyn March1,2, Lee S Simon1,2, Jasvinder A Singh1,2, Vibeke Strand1,2, George A Wells1,2, Peter Tugwell1,2. 1. From the Department of Epidemiology and Biostatistics, Amsterdam UMC, Vrije Universiteit; Department of Medical Humanities, VU University Medical Centre/EMGO+ institute, Amsterdam, the Netherlands; Institute for Work & Health and Institute for Health Policy Management and Evaluation, University of Toronto, Toronto; Centre for Practice-Changing Research, Ottawa Hospital Research Institute; Cardiovascular Research Methods Centre, University of Ottawa Heart Institute; Division of Rheumatology, Department of Medicine, and School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa; Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario; McGill Centre for Outcomes Research and Evaluation, Montreal, Quebec, Canada; Division of Rheumatology, Department of Medicine, Johns Hopkins University, Baltimore, Maryland; Medicine Service, VA Medical Center; Department of Medicine, School of Medicine, University of Alabama; Division of Epidemiology, School of Public Health, University of Alabama, Birmingham, Alabama; SDG LLC, Cambridge, Massachusetts; Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California, USA; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and UK National Institute for Health Research (NIHR) Leeds Musculoskeletal Biomedical Research Unit, Leeds, UK; Hôpital Ambroise Paré, Rheumatology Department, Boulogne-Billancourt; INSERM U1173, Laboratoire d'Excellence INFLAMEX, UFR Simone Veil, Versailles-Saint-Quentin University, Saint-Quentin en Yvelines; Sorbonne Université; Pitié Salpêtrière hospital, AP-HP, Rheumatology Department, Paris, France; Sydney Medical School, Institute of Bone and Joint Research; Department of Rheumatology, Royal North Shore Hospital, St Leonards, Australia. 2. M. Boers, MD, PhD, Professor of Clinical Epidemiology, Amsterdam UMC, Vrije Universiteit Amsterdam; D.E. Beaton, PhD, Senior Scientist, Institute for Work & Health, and Associate Professor, Institute Health Policy, Management and Evaluation, University of Toronto; B.J. Shea, PhD, Senior Scientist, Ottawa Hospital Research Institute, Clinical Epidemiology Program, and School of Epidemiology, Public Health and Preventive Medicine, Faculty of Medicine, University of Ottawa; L.J. Maxwell, PhD, University of Ottawa and Centre for Practice-Changing Research, Ottawa Hospital Research Institute; S.J. Bartlett, PhD, Professor of Medicine, McGill University, Centre for Outcomes Research and Evaluation, and Division of Rheumatology, Department of Medicine, Johns Hopkins University; C.O. Bingham III, MD, Division of Rheumatology, Department of Medicine, Johns Hopkins University; P.G. Conaghan, MBBS, PhD, FRACP, FRCP, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre; M.A. D'Agostino, MD, PhD, AP-HP, Professor of Rheumatology, Hôpital Ambroise Paré, Rheumatology Department, and INSERM U1173, Laboratoire d'Excellence INFLAMEX, UFR Simone Veil, Versailles-Saint-Quentin University; M.P. de Wit, PhD, OMERACT Patient Research Partner, and Amsterdam University Medical Centre, Department of Medical Humanities, Amsterdam Public Health; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 06, and AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology; L. March, MBBS, PhD, Liggins Professor of Rheumatology and Musculoskeletal Epidemiology, Sydney Medical School, Institute of Bone and Joint Research, and Department of Rheumatology, Royal North Shore Hospital; J.A. Singh, MBBS, MPH, Professor of Medicine and Epidemiology, Department of Medicine at the School of Medicine, University of Alabama at Birmingham; L.S. Simon, MD, Co-Managing Director of SDG LLC; V. Strand, MD, Biopharmaceutical Consultant, Portola Valley, California, USA; G.A. Wells, MSc, PhD, Director, Cardiovascular Research Methods Centre, University of Ottawa Heart Institute, and Professor, Department of Epidemiology and Community Medicine, University of Ottawa; P. Tugwell, MD, MSc, Professor, Division of Rheumatology, Department of Medicine, and School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, and Clinical Epidemiology Program, Ottawa Hospital Research Institute.
Abstract
OBJECTIVE: The Outcome Measures in Rheumatology (OMERACT) Filter 2.0 framework was developed in 2014 to aid core outcome set development by describing the full universe of "measurable aspects of health conditions" from which core domains can be selected. This paper provides elaborations and updated concepts (OMERACT Filter 2.1). METHODS: At OMERACT 2018, we discussed challenges in the framework application caused by unclear or ambiguous wording and terms and incompletely developed concepts. RESULTS: The updated OMERACT Filter 2.1 framework makes benefits and harms explicit, clarifies concepts, and improves naming of various terms. CONCLUSION: We expect that the Filter 2.1 framework will improve the process of core set development.
OBJECTIVE: The Outcome Measures in Rheumatology (OMERACT) Filter 2.0 framework was developed in 2014 to aid core outcome set development by describing the full universe of "measurable aspects of health conditions" from which core domains can be selected. This paper provides elaborations and updated concepts (OMERACT Filter 2.1). METHODS: At OMERACT 2018, we discussed challenges in the framework application caused by unclear or ambiguous wording and terms and incompletely developed concepts. RESULTS: The updated OMERACT Filter 2.1 framework makes benefits and harms explicit, clarifies concepts, and improves naming of various terms. CONCLUSION: We expect that the Filter 2.1 framework will improve the process of core set development.
Entities:
Keywords:
HEALTH STATUS INDICATOR; MEASUREMENT MODEL; OMERACT; PATIENT OUTCOME; THEORETICAL FRAMEWORK
Authors: David Roofeh; Shaney L Barratt; Athol U Wells; Leticia Kawano-Dourado; Donald Tashkin; Vibeke Strand; James Seibold; Susanna Proudman; Kevin K Brown; Paul F Dellaripa; Tracy Doyle; Thomas Leonard; Eric L Matteson; Chester V Oddis; Joshua J Solomon; Jeffrey A Sparks; Robert Vassallo; Lara Maxwell; Dorcas Beaton; Robin Christensen; Whitney Townsend; Dinesh Khanna Journal: Semin Arthritis Rheum Date: 2021-08-20 Impact factor: 5.431
Authors: Alison H Kohn; Afsaneh Alavi; April W Armstrong; Folawiyo Babalola; Amit Garg; Alice B Gottlieb; Lesley Grilli; Gregor Borut Ernst Jemec; John Latella; Kendall Marcus; Joseph F Merola; Alex G Ortega-Loayza; Daniel M Siegel; Vibeke Strand; Jerry K L Tan; Lourdes M Perez-Chada Journal: Dermatology Date: 2021-09-17 Impact factor: 5.197
Authors: Alain Lescoat; Susan L Murphy; David Roofeh; John D Pauling; Michael Hughes; Robert Sandler; François Zimmermann; Rachel Wessel; Whitney Townsend; Lorinda Chung; Christopher P Denton; Peter A Merkel; Virginia Steen; Yannick Allanore; Francesco Del Galdo; Dominique Godard; David Cella; Sue Farrington; Maya H Buch; Dinesh Khanna Journal: J Scleroderma Relat Disord Date: 2020-10-05
Authors: Alain Lescoat; David Roofeh; Whitney Townsend; Michael Hughes; Robert D Sandler; François Zimmermann; John D Pauling; Maya H Buch; Dinesh Khanna Journal: BMJ Open Date: 2021-03-11 Impact factor: 2.692
Authors: Tobias Tritschler; Nicole Langlois; Brian Hutton; Beverley J Shea; Risa Shorr; Sara Ng; Suzanne Dubois; Carol West; Alfonso Iorio; Peter Tugwell; Grégoire Le Gal Journal: BMJ Open Date: 2020-12-07 Impact factor: 2.692
Authors: Nathan A Pearson; Elizabeth Tutton; Alexander Joeris; Stephen Gwilym; Richard Grant; David J Keene; Kirstie L Haywood Journal: Trials Date: 2021-07-12 Impact factor: 2.279
Authors: Fumio Hirano; Désirée van der Heijde; Floris A van Gaalen; Robert B M Landewé; Cécile Gaujoux-Viala; Sofia Ramiro Journal: Rheumatology (Oxford) Date: 2021-01-05 Impact factor: 7.580